SymBio Pharmaceuticals Limited
SYMQY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,452,912 | $5,589,708 | $10,008,338 | $8,252,582 |
| % Growth | -56.1% | -44.1% | 21.3% | – |
| Cost of Goods Sold | $579,723 | $1,178,694 | $2,408,434 | $2,452,471 |
| Gross Profit | $1,873,189 | $4,411,014 | $7,599,904 | $5,800,111 |
| % Margin | 76.4% | 78.9% | 75.9% | 70.3% |
| R&D Expenses | $0 | $2,638,000 | $2,554,799 | $1,736,126 |
| G&A Expenses | $151,000 | $130,000 | $122,000 | $1,336,687 |
| SG&A Expenses | $2,371,000 | $2,584,000 | $3,081,479 | $2,979,246 |
| Sales & Mktg Exp. | $692,000 | $937,000 | $1,481,000 | $1,642,559 |
| Other Operating Expenses | $3,379,160 | $0 | -$54,158 | $4,565 |
| Operating Expenses | $5,750,160 | $5,222,682 | $5,636,278 | $4,784,109 |
| Operating Income | -$3,876,971 | -$811,668 | $1,963,625 | $1,016,001 |
| % Margin | -158.1% | -14.5% | 19.6% | 12.3% |
| Other Income/Exp. Net | $70,014 | -$383,719 | $142,654 | -$14,670 |
| Pre-Tax Income | -$3,806,957 | -$1,195,387 | $2,106,279 | $1,001,331 |
| Tax Expense | $26,523 | $767,429 | $927,041 | -$1,030,871 |
| Net Income | -$3,833,480 | -$1,962,817 | $1,179,238 | $2,032,203 |
| % Margin | -156.3% | -35.1% | 11.8% | 24.6% |
| EPS | -84.06 | -49.19 | 30.2 | 53.04 |
| % Growth | -70.9% | -262.9% | -43.1% | – |
| EPS Diluted | -84.06 | -49.19 | 29.77 | 52.32 |
| Weighted Avg Shares Out | 45,604 | 39,902 | 39,047 | 38,313 |
| Weighted Avg Shares Out Dil | 45,604 | 39,902 | 39,605 | 38,840 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32,116 | $11,000 | $98 | $125 |
| Interest Expense | $19,945 | $10,506 | $0 | $1,950 |
| Depreciation & Amortization | $98,000 | $96,005 | $98,092 | $93,959 |
| EBITDA | -$3,778,972 | -$715,663 | $2,061,718 | $1,109,960 |
| % Margin | -154.1% | -12.8% | 20.6% | 13.4% |